Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells
Journal of Biological Chemistry · 2024
DOI: 10.1016/j.jbc.2024.107375 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024. Verfasst von Lei Duan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois, USA. Electronic address: Lei_Duan@rush.edu. Hauptthemen laut MEDLINE: Myeloid Cell Leukemia Sequence 1 Protein, Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Department of Defense Peer Reviewed Cancer Research Program, Swim Across America.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is an aggressive breast cancer sub-type with limited treatment options and poor prognosis. Currently, standard treatments for TNBC include surgery, chemotherapy, and anti-PDL1 therapy. These therapies have limited efficacy in advanced stages. Myeloid-cell leukemia 1 (MCL1) is an anti-apoptotic BCL2 family protein. High expression of MCL1 contributes to chemotherapy resistance and is associated with a worse prognosis in TNBC. MCL1 inhibitors are in clinical trials for TNBC, but response rates to these inhibitors can vary and predictive markers are lacking. Currently, we identified a 4-member (AXL, ETS1, IL6, EFEMP1) gene signature (GS) that predicts MCL1 inhibitor sensitivity in TNBC cells. Factors encoded by these genes regulate signaling pathways to promote MCL1 inhibitor resistance. Small molecule inhibitors of the GS factors can overcome resistance and sensitize otherwise resistant TNBC cells to MCL1 inhibitor treatment. These findings offer insights into potential therapeutic strategies and tumor stratification for MCL1 inhibitor use in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois, USA. Electronic address: Lei_Duan@rush.edu.
- Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois, USA.
- Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois, USA. Electronic address: Carl_Maki@rush.edu.
Förderung
- NCI NIH HHS
- Department of Defense Peer Reviewed Cancer Research Program
- Swim Across America
- U.S. Department of Defense
- National Institutes of Health
Zitieren
APA
Duan, L., Tadi, M. J., O'Hara, K. M., & Maki, C. G. (2024). Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2024.107375
Vancouver
Duan L, Tadi MJ, O'Hara KM, Maki CG. Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. Journal of Biological Chemistry. 2024. doi:10.1016/j.jbc.2024.107375
BibTeX
@article{Duan2024,
author = {Duan, Lei and Tadi, Mehrdad Jafari and O'Hara, Kelsey M and Maki, Carl G},
title = {Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells},
journal = {Journal of Biological Chemistry},
year = {2024},
doi = {10.1016/j.jbc.2024.107375}
}
EUVIMED